What are the recommended treatments for acute seizures and chronic epilepsy?

Treatment for Seizures

For acute seizures and status epilepticus, benzodiazepines are first-line treatment, followed by valproate (20-30 mg/kg at 40 mg/min) as the preferred second-line agent over phenytoin/fosphenytoin due to superior efficacy (79% vs 25% seizure control), faster administration, and fewer adverse effects including no hypotension risk. 1

Acute Seizure Management (Status Epilepticus)

First-Line Treatment

• Benzodiazepines are mandatory initial therapy for any seizure lasting >5 minutes 1
• IV lorazepam preferred over diazepam when IV access available 2
• Rectal diazepam when IV access unavailable 2

Second-Line Treatment (After Benzodiazepine Failure)

Valproate is the superior choice based on Class II evidence showing:

• 79% seizure control vs 25% with phenytoin (absolute risk reduction 54%, NNT 1.9) 1
• No hypotension (vs 12% with phenytoin) 1
• Faster administration rate (40 mg/min vs phenytoin's 50 mg/min) 1
• Dose: 20-30 mg/kg IV at 40 mg/min 1

Alternative second-line options (Level B recommendations) 1:

• Phenytoin: 18-20 mg/kg (caution: hypotension, cardiac dysrhythmias, soft tissue injury)
• Fosphenytoin: 18-20 PE/kg (fewer local complications than phenytoin)
• Levetiracetam: 30-50 mg/kg at 100 mg/min (Level C, limited to Class III evidence showing 44-73% efficacy) 1

Third-Line Treatment (Refractory Status Epilepticus)

For seizures continuing after benzodiazepines + second-line agent:

• Propofol: 2 mg/kg bolus, repeat in 3-5 min, then 5 mg/kg/hr infusion

  • Requires fewer ventilation days than pentobarbital (4 vs 14 days) 1
  • Less hypotension than barbiturates (42% vs 77%) 1

• Phenobarbital: 10-20 mg/kg, may repeat 5-10 mg/kg at 10 min

  • 58.2% efficacy as initial medication in Class I trial 1
  • Major limitation: respiratory depression and hypotension 1

Chronic Epilepsy Management

Monotherapy Selection

For partial (focal) seizures:

• Adults: Carbamazepine or lamotrigine 3
• Children: Oxcarbazepine 3
• Elderly: Lamotrigine or gabapentin 3

For generalized seizures:

• Valproate is first-line 3
• Avoid valproate in women of childbearing age due to teratogenicity 2, 3
• Alternative: Consider carbamazepine based on individual risk-benefit 2

Standard First-Line Monotherapy Options

Per WHO guidelines, any of these are acceptable for convulsive epilepsy 2:

• Carbamazepine (preferred for partial onset seizures)
• Phenobarbital (most cost-effective if availability assured)
• Phenytoin
• Valproic acid

Key Treatment Principles

Start treatment when:

• After second unprovoked seizure (defines epilepsy) 2
• Consider after first unprovoked seizure if: abnormal EEG, abnormal imaging, or severe social/personal implications 3
• Do NOT routinely treat first unprovoked seizure 2

Discontinuation:

• Consider stopping after 2 seizure-free years 2
• Requires individualized assessment of clinical, social, and personal factors 2

Critical Pitfalls to Avoid

1. Underdosing second-line agents: Use full loading doses (valproate 20-30 mg/kg, not lower)
2. Delaying second-line treatment: Administer immediately after benzodiazepine failure, not after prolonged observation
3. Using phenytoin as default: Valproate has superior evidence for efficacy and safety profile 1
4. Missing underlying causes: Simultaneously treat hypoglycemia, hyponatremia, hypoxia, infection, or withdrawal 1
5. Premature polytherapy: Optimize monotherapy dosing before adding second agent 2
6. Valproate in pregnancy: Absolutely avoid due to teratogenicity; use folic acid supplementation with any AED 2

Acute Symptomatic Seizures

Short-term ASM treatment (days to weeks) is appropriate for seizures occurring with:

• Subdural hemorrhage
• Traumatic brain injury
• Cortical stroke
• CNS infection
• Metabolic derangements

Consider longer treatment (few months) if persistent epileptiform activity on EEG or structural brain changes on imaging 4, 5